Can a new PET tracer reveal hidden immune clues in tumors?

NCT ID NCT04605614

First seen Aug 12, 2026 · Last updated Aug 13, 2026 · Updated 1 time

Summary

This phase I trial tests an experimental imaging agent called 64Cu-DOTA-pembrolizumab, which is designed to attach to PD1, a protein on immune cells that often cluster around tumors. By injecting this agent and then performing a PET scan, researchers hope to see where these immune cells are in the body, potentially detecting them even when they are too small for standard scans. The study includes people with certain blood or solid tumors who plan to receive immunotherapy. The main goals are to find the safest dose and to see if this imaging method can help predict whether a patient will respond to immunotherapy.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Copper Cu 64-DOTA-pembrolizumab, a radiotracer that binds to PD1 on immune cells, given intravenously before a PET scan
What this could lead to
If successful, this imaging approach could help doctors see whether a patient's tumor has the right immune cells to respond to immunotherapy, guiding treatment decisions.
What could go wrong
This is an early-phase trial focused on safety and dosing, so the imaging agent may not prove accurate or beneficial. There are also risks from radiation exposure and potential side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEMATOPOIETIC AND LYMPHOID CELL NEOPLASM are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

More trials for these conditions

Other studies related to the condition(s) this trial covers.